Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

175.99 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

57 58 Next >

Why Are Cruise Stocks CCL, RCL, NCLH Up Today? ↗

June 12, 2023

Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details!

Via InvestorPlace

BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing ↗

June 12, 2023

Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday.

Via InvestorPlace

Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗

June 12, 2023

Via Benzinga

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

June 09, 2023

From Biogen Inc.

Via GlobeNewswire

Expert Ratings for Biogen ↗

June 08, 2023

Via Benzinga

$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

June 05, 2023

Via Benzinga

Biogen Unusual Options Activity For May 26 ↗

May 26, 2023

Via Benzinga

Analyst Ratings for Biogen ↗

May 23, 2023

Via Benzinga

Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment ↗

June 09, 2023

A panel of experts will debate the merits of Biogen's drug, Leqembi.

Via Investor's Business Daily

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗

June 08, 2023

Senator Bernie Sanders urged the U.S.

Via Benzinga

FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval ↗

June 08, 2023

FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for...

Via Benzinga

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near ↗

June 07, 2023

The FDA's advisors will consider the full approval of Leqembi on Friday.

Via Investor's Business Daily

Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio ↗

June 07, 2023

When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several...

Via Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today ↗

May 19, 2023

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

May 10, 2023

Via Benzinga

Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗

June 05, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump ↗

June 01, 2023

The news also benefits Biogen's partner Eisai and rival Eli Lilly.

Via Investor's Business Daily

How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗

June 01, 2023

Shares surged into and out of the company's R&D Day, which included a surprise.

Via Investor's Business Daily

Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption? ↗

May 30, 2023

A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.

Via Talk Markets

3 Biotech Stocks That Are Revolutionizing Healthcare in 2023 ↗

May 19, 2023

Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.

Via InvestorPlace

1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market ↗

May 19, 2023

Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.

Via The Motley Fool

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

Via MarketBeat

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

May 15, 2023

From Biogen Inc.

Via GlobeNewswire

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says. ↗

May 15, 2023

An analyst says Lilly's donanemab could become a blockbuster in its second year on the market.

Via Investor's Business Daily

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win ↗

May 14, 2023

There's no rule that says a market must have only one winner.

Via The Motley Fool

3 Reasons to Buy Biogen Stock (and 1 to Sell) ↗

May 12, 2023

The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.

Via The Motley Fool

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors ↗

May 12, 2023

The biotech's prospects continue to get brighter.

Via The Motley Fool

Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal ↗

May 11, 2023

Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.

Via The Motley Fool

Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗

May 09, 2023

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today